Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129096) titled 'Diagnostic Value of Serum Anti-CENPF Autoantibodies in Ground-Glass Nodule-Associated Lung Adenocarcinoma: A Multicenter Prospective Trial' on July 30.
Study Type: Diagnostic test
Study Design:
Diagnostic test for accuracy
Primary Sponsor: Tangdu Hospital
Condition:
Lung cancer
Intervention:
Gold Standard:Postoperative pathology was the gold standard according to the 2021 edition of WHO"Pathological diagnostic criteria for lung tumors", which was finally approved by two senior pathologists
Recruitment Status: Not Recruiting
Phase: Diagnostic New Technique Clincal Study
Date of First Enrollment: 2026-07...